Strong finish to 2020 for Dechra
Animal medicine maker Dechra Pharmaceuticals says it finished 2020 strongly with an excellent performance in the first half of its financial year.
The group, which has a site near Shrewsbury, saw revenue grow 21.8% to £299.8m in the six months to the end of December.
Chief executive Ian Page said it was despite 2020 being one of the most challenging years in Dechra's history.
Operating profit improved 73% to £40.3m.
Mr Page said revenue growth had been strong, especially within companion animal products, as pet ownership and welfare has become more important to people as the Covid-19 pandemic has changed peoples' way of living.
The group also benefited from a significantly improved supply chain and a pre-Brexit inventory build.
Mr Page said the level of dedication and commitment from its people throughout the Covid-19 pandemic had remained exceptional and despite increased levels of absence, particularly in manufacturing sites, it had managed to keep all key functions operational.
